Clinical Trial Update: Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial update of a Bruton's tyrosine kinase inhibitor in relapsed/refractory multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bruton's Tyrosine Kinase inhibitor

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2018-06-26